title: NRF2 as an Emerging Therapeutic Target.
authors.affiliation: MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool L69 3GE, UK.
authors.forename: Ian M
authors.identifier: 0000-0003-4101-1913
authors.initials: IM
authors.lastname: Copple
authors.affiliation: Division of Cancer Research, School of Medicine, University of Dundee, Dundee DD1 9SY, UK.
authors.forename: Albena T
authors.initials: AT
authors.lastname: Dinkova-Kostova
authors.affiliation: Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA 15261, USA.
authors.forename: Thomas W
authors.initials: TW
authors.lastname: Kensler
authors.affiliation: Department of Pharmacology and Toxicology, Michigan State University, East Lansing, MI 48824, USA.
authors.forename: Karen T
authors.initials: KT
authors.lastname: Liby
authors.affiliation: Reata Pharmaceuticals Inc., 2801 Gateway Drive, Irving, TX 75063, USA.
authors.forename: W Christian
authors.initials: WC
authors.lastname: Wigley
mesh_terms: D000818:Animals; D006801:Humans; D051267:NF-E2-Related Factor 2 / Q000378:metabolism*; D018384:Oxidative Stress / Q000502:physiology*
chemical_list: D051267:NF-E2-Related Factor 2